Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
BERKELEY, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its first quarter 2019 financial results on
View HTML
Toggle Summary Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
BERKELEY, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present data from a Phase 1b/2
View HTML
Toggle Summary Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
Using an investigational safety treatment regimen, inhaled DV281 in combination with systemic nivolumab was well tolerated in a population of heavily pre-treated NSCLC patients Target engagement was observed at all dose levels Evidence of anti-tumor effects was seen at all dose levels BERKELEY,
View HTML
Toggle Summary Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany , April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) and 4SC AG (FSE Prime Standard: VSC) today announced the combination of 4SC’s orally available class I selective HDAC inhibitor domatinostat (4SC-202) with
View HTML
Toggle Summary Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
BERKELEY, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has
View HTML
Toggle Summary Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
BERKELEY, Calif. , March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present safety and biomarker data for
View HTML
Toggle Summary Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
Proceeds to fund HEPLISAV-B® commercialization activities and completion of ongoing immuno-oncology studies BERKELEY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has exercised its option to draw down $75 million of non-dilutive
View HTML
Toggle Summary Dynavax to Present at 39th Annual Cowen Healthcare Conference
BERKELEY, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray , Chief Executive Officer, will
View HTML
Toggle Summary Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter 2018 HEPLISAV-B ® net product revenue of $3.9 million Phase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual Meeting SD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapy Conference call to be held today at 4:30 p.m. ET / 1:30 p.m.
View HTML
Toggle Summary Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
BERKELEY, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its fourth quarter and full year 2018 financial
View HTML